 |
|
 |
 |
|
||||||||||||||
|
Diet drug Acomplia permitted for Sale in Switzerland 5 April 2007 Diet drug Acomplia (rimonabant) has been given permission for sale in Switzerland for the treatment of obese or overweight patients with at least one type of associated cardiovascular ailment. Sanofi-Aventis, the firm manufacturing Acomplia, said Swiss medic authorized the use of the Acomplia for obese patients whose body mass index (BMI) are greater than 30 or for overweight patients whose body mass index (BMI) are over 27 with at least one associated cardiovascular risk factor. The other condition is that they should have tried weight reduction that should have failed. The approval by Switzerland is akin to the EU marketing approval that was cleared last June, where the drug was cleared for use in conjunction with diet and exercise for overweight and obese patients with linked health risks such as type 2 diabetes. The recent disappointment faced by the firm with France and Germany's
policy on reimbursements will not be eased by the clearance of Acomplia
in Switzerland, which is a small country. |
||||||||||||||
